Abstract

Background

The legal background of the current pharmaceutical pricing and reimbursement (P marketing authorization holders and insurance funds (IFs) also participate.

Objectives

To present a general overview of the current Czech health care system and its PR principles.

Methods

The study used publicly available sources concerning health care, mainly acts related to public health care and public health care insurance, public notices related to PR setting, and statistical data.

Results

Regulation covers P ∼€600,000 to €1.8 million) to enter the system. Products exceeding this budget impact have to negotiate risk-sharing schemes, mainly further discounts and/or budget caps.

Conclusions

The Czech pricing and reimbursement system is rather complex, taking into account clinical evidence, cost-effectiveness and budget impact. The strict regulations are a result of financial scarcity.